Cue Biopharma, Inc. Capital Expenditures Incurred but Not yet Paid
Cue Biopharma, Inc. (CUE) reported Capital Expenditures Incurred but Not yet Paid of $140.65 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2020-05-07
- Cue Biopharma, Inc. capital expenditures incurred but not yet paid for the quarter ending 2020-03-31 was $140.65M.
- Cue Biopharma, Inc. capital expenditures incurred but not yet paid for the quarter ending 2018-03-31 was $227.00K, a 682.76% increase year-over-year.
- Cue Biopharma, Inc. capital expenditures incurred but not yet paid for the quarter ending 2017-03-31 was $29.00K.
- Cue Biopharma, Inc. capital expenditures incurred but not yet paid for fiscal 2017 was $67.48K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|
| 2020-03-31 | $140.65M 10-Q · filed 2020-05-07 | |
| 2018-03-31 | $227.00K 10-Q · filed 2019-05-08 | |
| 2017-12-31 | $67.48K 10-K · filed 2019-03-14 | |
| 2017-03-31 | $29.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |